Free Trial
→ Uranium Mine Flood That Sparked a 2006 Price Surge Returns (From Digest Publishing) (Ad)tc pixel Free STIM Stock Alerts

Neuronetics (STIM) Financials

Neuronetics logo
$1.39 -0.04 (-2.80%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$1.41 +0.02 (+1.44%)
As of 11/13/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Neuronetics

Annual Income Statements for Neuronetics

This table shows Neuronetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -11 -16 -24 -29 -27 -31 -37 -30 -44 -39
Consolidated Net Income / (Loss)		 -11 -16 -24 -29 -27 -31 -37 -30 -44 -39
Net Income / (Loss) Continuing Operations		 -11 -16 -24 -29 -27 -31 -37 -30 -44 -39
Total Pre-Tax Income 		-11 -16 -24 -29 -27 -31 -37 -30 -44 -39
Total Operating Income		 -9.34 -14 -20 -27 -22 -28 -35 -31 -35 -31
Total Gross Profit		 28 31 40 47 38 44 50 52 54 72
Total Revenue		 34 40 53 63 49 55 65 71 75 149
Operating Revenue		 34 40 53 63 49 55 65 71 75 149
Total Cost of Revenue		 6.62 9.63 12 15 12 12 15 20 21 77
Operating Cost of Revenue		 6.62 9.63 12 15 12 12 15 20 21 77
Total Operating Expenses		 37 44 60 74 60 71 85 82 89 104
Selling, General & Admin Expense		 6.93 8.57 14 17 18 26 26 25 30 50
Marketing Expense		 22 28 38 43 33 38 50 47 46 47
Research & Development Expense		 8.22 7.94 8.23 14 9.20 7.92 9.34 9.52 13 6.58
Total Other Income / (Expense), net		 -1.90 -2.45 -4.26 -2.11 -5.14 -3.63 -2.05 0.37 -9.16 -7.70
Interest Expense		 1.84 2.81 3.69 3.69 5.45 4.02 4.25 5.42 12 8.42
Other Income / (Expense), net		 -0.06 0.36 -0.58 1.57 0.30 0.39 2.20 5.79 2.55 0.72
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - - - 0.00 0.00 -0.02 -0.14
Basic Earnings per Share		 ($76.95) ($86.34) ($2.69) ($1.58) ($1.46) ($1.22) ($1.38) ($1.05) ($1.38) ($0.59)
Weighted Average Basic Shares Outstanding		 146K 186K 8.95M 18.38M 18.84M 25.48M 26.90M 28.66M 31.73M 65.95M
Diluted Earnings per Share		 ($76.95) ($86.34) ($2.69) ($1.58) ($1.46) ($1.22) ($1.38) ($1.05) ($1.38) ($0.59)
Weighted Average Diluted Shares Outstanding		 146K 186K 8.95M 18.38M 18.84M 25.48M 26.90M 28.66M 31.73M 65.95M
Weighted Average Basic & Diluted Shares Outstanding		 146K 186K 8.95M 18.38M 18.84M 26.63M 28.36M 29.76M 65.81M 69.28M

Quarterly Income Statements for Neuronetics

This table shows Neuronetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -7.87 -9.83 -13 -13 -13 -10 -9.05 -7.16 -11 -3.44 -1.69
Consolidated Net Income / (Loss)		 -7.87 -9.83 -13 -13 -13 -9.84 -9.40 -7.21 -11 -3.46 -1.56
Net Income / (Loss) Continuing Operations		 -7.87 -9.83 -13 -13 -13 -9.84 -9.40 -7.21 -11 -3.46 -1.56
Total Pre-Tax Income 		-7.87 -9.83 -13 -13 -13 -9.84 -9.40 -7.21 -11 -3.46 -1.56
Total Operating Income		 -6.86 -8.51 -7.73 -11 -11 -8.06 -7.32 -5.04 -9.00 -1.50 0.54
Total Gross Profit		 13 12 14 15 16 18 17 22 16 21 22
Total Revenue		 17 16 19 22 32 38 37 42 34 42 42
Operating Revenue		 17 16 19 22 32 38 37 42 34 42 42
Total Cost of Revenue		 4.33 4.27 4.53 7.60 16 20 20 20 18 20 20
Operating Cost of Revenue		 4.33 4.27 4.53 7.60 16 20 20 20 18 20 20
Total Operating Expenses		 20 21 22 26 27 26 24 27 25 23 21
Selling, General & Admin Expense		 5.96 6.15 7.44 11 13 12 11 13 13 11 12
Marketing Expense		 12 12 12 9.81 12 12 12 12 11 9.98 8.48
Research & Development Expense		 2.35 2.24 2.42 5.77 1.62 1.80 1.50 1.67 1.36 1.34 1.19
Total Other Income / (Expense), net		 -1.01 -1.33 -5.61 -1.21 -1.68 -1.78 -2.08 -2.16 -1.79 -1.96 -2.10
Interest Expense		 1.83 1.98 6.15 1.76 1.92 1.97 2.21 2.32 2.81 2.13 2.14
Other Income / (Expense), net		 0.81 0.65 0.54 0.55 0.25 0.19 0.13 0.16 1.02 0.16 0.05
Net Income / (Loss) Attributable to Noncontrolling Interest		 0.00 0.00 0.00 - -0.01 0.28 -0.36 -0.05 0.01 -0.03 0.14
Basic Earnings per Share		 ($0.27) ($0.33) ($0.44) ($0.34) ($0.21) ($0.15) ($0.13) ($0.10) ($0.16) ($0.05) ($0.02)
Weighted Average Basic Shares Outstanding		 29.47M 30.05M 30.27M 31.73M 61.47M 66.18M 67.31M 65.95M 69.59M 73.13M 77.00M
Diluted Earnings per Share		 ($0.27) ($0.33) ($0.44) ($0.34) ($0.21) ($0.15) ($0.13) ($0.10) ($0.16) ($0.05) ($0.02)
Weighted Average Diluted Shares Outstanding		 29.47M 30.05M 30.27M 31.73M 61.47M 66.18M 67.31M 65.95M 69.59M 73.13M 77.00M
Weighted Average Basic & Diluted Shares Outstanding		 30.00M 30.30M 30.35M 65.81M 65.82M 66.12M 68.49M 69.28M 69.59M 76.20M 77.73M

Annual Cash Flow Statements for Neuronetics

This table details how cash moves in and out of Neuronetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -3.97 12 75 -29 -27 45 -24 -11 -40 15
Net Cash From Operating Activities		 -8.54 -11 -21 -30 -28 -28 -31 -32 -31 -20
Net Cash From Continuing Operating Activities		 -8.54 -11 -21 -30 -28 -28 -31 -32 -31 -20
Net Income / (Loss) Continuing Operations		 -11 -16 -24 -29 -27 -31 -37 -30 -44 -39
Consolidated Net Income / (Loss)		 -11 -16 -24 -29 -27 -31 -37 -30 -44 -39
Depreciation Expense		 0.67 0.60 0.88 1.07 0.94 1.06 1.65 2.01 2.07 3.47
Amortization Expense		 0.39 0.72 0.84 0.75 1.19 0.72 0.71 0.63 0.77 0.82
Non-Cash Adjustments To Reconcile Net Income		 0.28 0.44 3.37 -3.42 4.43 7.23 10 11 18 7.86
Changes in Operating Assets and Liabilities, net		 1.35 3.16 -1.58 0.17 -7.50 -5.80 -6.23 -15 -7.81 6.61
Net Cash From Investing Activities		 -0.32 -0.59 -1.01 -0.81 -0.73 -9.84 6.73 -1.32 -2.41 -0.80
Net Cash From Continuing Investing Activities		 -0.32 -0.59 -1.01 -0.81 -0.73 -9.84 6.73 -1.32 -2.41 -0.80
Purchase of Property, Plant & Equipment		 -0.32 -0.59 -1.01 -0.81 -0.73 -2.35 -3.27 -2.37 -1.47 -0.80
Acquisitions		 - - - - - - 0.00 0.00 -2.55 0.00
Other Investing Activities, net		 - - - 0.00 0.00 -7.49 10 1.05 1.61 0.00
Net Cash From Financing Activities		 4.90 24 97 2.42 2.37 83 0.21 23 -6.81 36
Net Cash From Continuing Financing Activities		 4.90 24 97 2.42 2.37 83 0.21 23 -6.81 36
Repayment of Debt		 -0.17 -1.02 0.00 0.00 -40 0.00 -0.09 -2.30 -67 -0.38
Repurchase of Common Equity		 - - -3.46 0.00 0.00 -0.40 - 0.00 0.00 -2.20
Payment of Dividends		 - - - - - - - 0.00 0.00 -0.09
Issuance of Debt		 5.00 10 0.00 0.00 41 0.00 0.00 25 57 10
Issuance of Common Equity		 - - 100 0.00 0.00 81 0.00 0.00 2.52 29
Other Financing Activities, net		 0.07 0.04 0.50 2.42 0.69 2.44 0.30 0.00 0.00 -0.49
Cash Interest Paid		 1.41 2.04 2.79 2.95 3.89 3.30 3.54 4.79 6.51 7.59

Quarterly Cash Flow Statements for Neuronetics

This table details how cash moves in and out of Neuronetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 -12 -5.09 -22 -1.41 1.77 -3.76 17 -0.34 -15 5.98 2.91
Net Cash From Operating Activities		 -12 -4.97 -5.42 -8.60 -17 -3.50 -0.79 0.91 -9.42 -1.01 1.24
Net Cash From Continuing Operating Activities		 -12 -4.97 -5.42 -8.60 -17 -3.50 -0.79 0.91 -9.42 -1.01 1.24
Net Income / (Loss) Continuing Operations		 -7.87 -9.83 -13 -13 -13 -9.84 -9.40 -7.21 -11 -3.46 -1.56
Consolidated Net Income / (Loss)		 -7.87 -9.83 -13 -13 -13 -9.84 -9.40 -7.21 -11 -3.46 -1.56
Depreciation Expense		 0.56 0.56 0.51 0.45 0.91 0.90 0.89 0.77 0.75 0.73 0.74
Amortization Expense		 0.16 0.31 0.11 0.19 0.19 0.20 0.21 0.22 0.26 0.22 0.23
Non-Cash Adjustments To Reconcile Net Income		 2.06 2.31 6.76 4.70 1.46 2.72 2.04 1.64 2.15 0.99 2.17
Changes in Operating Assets and Liabilities, net		 -6.92 1.69 0.55 -1.25 -6.87 2.51 5.48 5.48 -1.79 0.51 -0.35
Net Cash From Investing Activities		 0.07 -0.12 0.01 -2.38 -0.22 -0.25 -0.11 -0.22 -0.17 -0.42 -0.47
Net Cash From Continuing Investing Activities		 0.07 -0.12 0.01 -2.38 -0.22 -0.25 -0.11 -0.22 -0.17 -0.42 -0.47
Purchase of Property, Plant & Equipment		 -0.38 -0.62 -0.39 -0.09 -0.22 -0.25 -0.11 -0.22 -0.20 -0.42 -0.47
Net Cash From Financing Activities		 0.00 - -16 9.56 19 0.00 18 -1.03 -5.58 7.41 2.14
Net Cash From Continuing Financing Activities		 0.00 - -16 9.56 19 0.00 18 -1.03 -5.58 7.41 2.14
Repurchase of Common Equity		 0.00 - - - -1.73 - -0.34 -0.14 0.00 -0.38 -0.03
Payment of Dividends		 - - - - 0.00 - - - -0.08 -0.12 -0.23
Issuance of Common Equity		 0.00 - 1.92 0.61 21 - 8.31 - 0.00 7.95 0.62
Other Financing Activities, net		 0.00 - 0.00 - 0.01 0.00 0.00 -0.50 -0.25 - 1.78
Cash Interest Paid		 1.67 1.66 1.62 1.57 1.73 1.76 1.99 2.12 2.01 1.91 1.93

Annual Balance Sheets for Neuronetics

This table presents Neuronetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 39 117 100 79 141 117 116 141 142
Total Current Assets		 37 114 88 65 115 99 94 58 62
Cash & Equivalents		 29 105 76 49 94 70 60 18 28
Restricted Cash		 - - - - - - 0.00 1.00 6.00
Short-Term Investments		 - - 0.88 1.89 2.20 1.54 0.91 0.21 0.23
Note & Lease Receivable		 - - - - 0.07 0.23 2.06 0.93 0.42
Accounts Receivable		 4.27 5.62 6.57 7.17 7.71 14 16 23 16
Inventories, net		 2.47 2.43 2.78 3.72 6.56 8.90 8.09 4.25 4.33
Prepaid Expenses		 1.12 1.84 2.52 3.28 4.65 4.17 7.28 9.92 5.97
Plant, Property, & Equipment, net		 1.36 1.38 1.11 0.73 1.22 1.99 2.01 6.24 4.47
Total Noncurrent Assets		 0.57 1.17 11 13 25 16 20 77 76
Long-Term Investments		 - - 1.73 2.33 1.70 1.22 0.66 0.09 0.10
Noncurrent Note & Lease Receivables		 - - - - 10 0.36 3.80 0.30 0.15
Goodwill		 - - - - - - 0.00 19 24
Intangible Assets		 - - - - - - 0.00 20 18
Other Noncurrent Operating Assets		 0.57 1.17 8.88 11 13 15 16 38 34
Total Liabilities & Shareholders' Equity		 39 117 100 79 141 117 116 141 142
Total Liabilities		 44 46 52 53 56 60 82 109 115
Total Current Liabilities		 12 14 28 14 16 33 20 31 31
Short-Term Debt		 - - 11 - 0.00 13 0.00 1.00 0.50
Accounts Payable		 2.51 3.76 4.63 3.75 4.30 2.43 4.75 11 11
Accrued Expenses		 7.51 7.55 9.03 7.32 8.23 15 13 13 12
Current Deferred Revenue		 1.97 2.26 2.23 2.02 2.50 1.98 1.62 0.97 0.75
Other Current Liabilities		 - - 0.56 0.59 0.67 0.82 0.85 5.40 6.21
Total Noncurrent Liabilities		 32 32 25 39 40 27 62 78 85
Long-Term Debt		 30 30 20 35 35 23 59 55 66
Noncurrent Deferred Revenue		 2.43 2.03 2.11 1.74 1.47 0.83 0.20 0.00 0.05
Other Noncurrent Operating Liabilities		 0.48 - 2.62 3.12 3.54 2.97 2.35 23 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -193 71 48 25 85 57 34 32 26
Total Preferred & Common Equity		 -193 71 48 25 85 57 34 28 22
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -193 71 48 25 85 57 34 28 22
Common Stock		 4.29 292 298 303 394 403 410 447 481
Retained Earnings		 -197 -221 -250 -278 -309 -346 -376 -420 -459
Noncontrolling Interest		 - - - - - - 0.00 4.09 3.86

Quarterly Balance Sheets for Neuronetics

This table presents Neuronetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 93 104 97 74 142 135 145 125 132 132
Total Current Assets		 71 82 76 53 61 56 65 47 53 54
Cash & Equivalents		 36 48 43 21 20 11 28 13 19 22
Restricted Cash		 - - - - 1.00 6.50 6.50 5.75 5.75 5.75
Short-Term Investments		 0.97 0.82 0.69 0.57 0.20 0.18 0.18 0.26 0.23 0.25
Note & Lease Receivable		 1.85 2.12 2.36 2.48 0.70 0.53 0.49 0.40 0.32 0.26
Accounts Receivable		 15 18 17 17 26 26 19 16 16 14
Inventories, net		 9.74 6.69 6.14 4.96 4.07 4.94 4.32 4.72 5.50 4.94
Prepaid Expenses		 7.59 7.00 6.53 7.76 8.28 6.91 6.73 7.03 6.28 6.15
Plant, Property, & Equipment, net		 2.07 1.85 1.73 1.64 5.85 5.32 4.94 3.87 3.46 3.18
Total Noncurrent Assets		 20 20 20 19 75 73 76 74 75 75
Long-Term Investments		 0.70 0.52 0.27 0.14 0.07 0.10 0.09 0.11 0.07 0.09
Noncurrent Note & Lease Receivables		 4.19 3.66 3.15 2.88 0.32 0.33 0.22 0.09 0.04 0.02
Goodwill		 - - - - 19 19 23 24 24 24
Intangible Assets		 - - - - 19 19 19 18 17 17
Other Noncurrent Operating Assets		 15 16 16 16 37 35 34 33 34 34
Total Liabilities & Shareholders' Equity		 93 104 97 74 142 135 145 125 132 132
Total Liabilities		 55 76 77 65 102 103 114 108 110 110
Total Current Liabilities		 15 14 29 17 25 28 29 28 28 27
Short-Term Debt		 0.00 - 14 - 1.00 1.00 1.00 0.25 0.25 0.25
Accounts Payable		 2.82 2.98 4.10 3.30 8.48 9.73 12 11 12 9.96
Accrued Expenses		 10 9.05 9.24 11 9.31 11 9.65 9.60 8.93 10
Current Deferred Revenue		 1.64 1.62 1.45 1.31 0.79 0.89 0.75 0.83 1.14 1.00
Other Current Liabilities		 0.84 0.85 0.86 0.86 5.27 5.60 5.96 6.17 5.57 5.29
Total Noncurrent Liabilities		 40 62 48 48 78 75 85 80 82 83
Long-Term Debt		 37 59 46 46 55 56 66 61 62 62
Noncurrent Deferred Revenue		 0.35 0.04 0.02 0.00 0.00 0.00 0.00 0.06 0.06 0.01
Other Noncurrent Operating Liabilities		 2.51 2.18 2.01 1.83 22 20 19 19 20 21
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 38 28 19 9.38 40 32 31 17 22 22
Total Preferred & Common Equity		 38 28 19 9.38 35 27 27 13 18 19
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 38 28 19 9.38 35 27 27 13 18 19
Common Stock		 409 412 413 417 468 470 479 483 491 494
Retained Earnings		 -371 -384 -394 -407 -432 -443 -452 -470 -473 -475
Noncontrolling Interest		 - - - - 4.08 4.36 4.00 3.80 3.79 3.70

Annual Metrics And Ratios for Neuronetics

This table displays calculated financial ratios and metrics derived from Neuronetics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 17,579,491.00 18,632,268.00 18,975,322.00 26,367,959.00 27,221,490.00 28,933,132.00 - 68,485,922.00
DEI Adjusted Shares Outstanding		 0.00 0.00 17,579,491.00 18,632,268.00 18,975,322.00 26,367,959.00 27,221,490.00 28,933,132.00 - 68,485,922.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.37 -1.56 -1.45 -1.18 -1.37 -1.04 - -0.57
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 18.13% 30.53% 18.72% -21.41% 12.32% 17.89% 9.42% 4.96% 99.17%
EBITDA Growth		 0.00% -43.17% -56.61% -25.97% 15.58% -27.80% -20.28% 27.58% -31.84% 9.39%
EBIT Growth		 0.00% -40.98% -54.02% -24.25% 13.22% -23.48% -21.10% 24.74% -29.27% 4.04%
NOPAT Growth		 0.00% -45.74% -45.75% -35.78% 17.16% -23.56% -27.38% 12.98% -13.12% 9.05%
Net Income Growth		 0.00% -42.95% -50.05% -20.53% 5.48% -13.62% -19.13% 18.76% -44.84% 10.50%
EPS Growth		 0.00% -12.20% 96.88% 41.26% 7.59% 16.44% -13.11% 23.91% -31.43% 57.25%
Operating Cash Flow Growth		 0.00% -30.48% -84.77% -48.04% 6.86% 1.43% -9.85% -4.23% 3.25% 34.27%
Free Cash Flow Firm Growth		 0.00% 0.00% -258.59% -43.13% 3.56% -59.25% 36.79% -53.08% -78.51% 80.23%
Invested Capital Growth		 0.00% 0.00% 38.40% 121.68% 917.30% 223.93% -11.39% 61.85% 111.60% -14.82%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 2.82% -3.48% -1.00% 5.12% 3.06% 3.00% 14.85%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -6.11% 15.99% -16.95% -0.76% 13.39% -34.18% 19.47%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -6.04% 15.39% -16.89% -1.56% 12.52% -30.01% 16.42%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -4.98% 16.09% -18.22% -2.38% 9.75% -25.59% 16.97%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -5.11% 12.43% -14.62% -1.79% 8.80% -20.05% 12.27%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -103.07% 12.57% -10.91% 0.72% 11.02% -14.05% 28.92%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -14.10% -15.66% 14.20% -11.21% 4.43% 14.04% -52.94% 31.81%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 12.14% -9.64% 3.00% 14.49% -280.98% 78.75%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -39.96% -6.50% -1.73% -7.64% -13.54% 101.75% -8.22%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 80.65% 76.18% 76.42% 75.44% 76.54% 78.93% 76.26% 72.47% 72.32% 48.48%
EBITDA Margin		 -24.35% -29.51% -35.41% -37.57% -40.36% -45.92% -46.85% -31.01% -38.95% -17.72%
Operating Margin		 -27.28% -33.66% -37.58% -42.98% -45.30% -49.83% -53.85% -42.82% -46.15% -21.08%
EBIT Margin		 -27.46% -32.77% -38.67% -40.47% -44.69% -49.13% -50.47% -34.71% -42.75% -20.60%
Profit (Net Income) Margin		 -32.82% -39.72% -45.66% -46.35% -55.75% -56.39% -56.99% -42.31% -58.39% -26.24%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 119.52% 121.19% 118.07% 114.53% 124.75% 114.79% 112.92% 121.90% 136.59% 127.39%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -409.88% -131.20% -115.97% -82.03% -48.18% -34.85%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -373.86% -101.92% -90.76% -37.02% -161.61% -85.05%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 335.02% 74.83% 63.72% 15.87% -84.35% -100.01%
Return on Equity (ROE)		 0.00% 291.13% -73.55% -48.86% -74.86% -56.37% -52.25% -66.17% -132.53% -134.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -3,325.37% -574.08% -236.85% -103.89% -129.27% -119.81% -18.84%
Operating Return on Assets (OROA)		 0.00% -34.03% -26.17% -23.35% -24.61% -24.72% -25.50% -21.28% -24.94% -21.75%
Return on Assets (ROA)		 0.00% -41.24% -30.90% -26.75% -30.70% -28.37% -28.79% -25.95% -34.06% -27.71%
Return on Common Equity (ROCE)		 0.00% 10,168.19% 136.50% -48.86% -74.86% -56.37% -52.25% -66.17% -124.31% -116.37%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 8.34% -33.92% -60.70% -107.69% -36.62% -65.12% 0.00% -157.83% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.54 -9.53 -14 -19 -16 -19 -25 -21 -24 -22
NOPAT Margin		 -19.10% -23.56% -26.31% -30.09% -31.71% -34.88% -37.69% -29.98% -32.31% -14.75%
Net Nonoperating Expense Percent (NNEP)		 0.00% 3,194.82% -27.69% -16.80% -36.02% -29.29% -25.20% -45.01% 113.43% 50.20%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -26.42% -22.88% -27.51% -23.78%
Cost of Revenue to Revenue		 19.35% 23.82% 23.58% 24.56% 23.46% 21.07% 23.74% 27.53% 27.68% 51.52%
SG&A Expenses to Revenue		 20.23% 21.20% 25.90% 27.86% 37.03% 46.20% 39.13% 35.64% 40.49% 33.32%
R&D to Revenue		 24.02% 19.63% 15.60% 21.94% 18.68% 14.32% 14.32% 13.34% 17.05% 4.41%
Operating Expenses to Revenue		 107.93% 109.83% 114.00% 118.42% 121.84% 128.77% 130.10% 115.29% 118.47% 69.55%
Earnings before Interest and Taxes (EBIT)		 -9.40 -13 -20 -25 -22 -27 -33 -25 -32 -31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.34 -12 -19 -24 -20 -25 -31 -22 -29 -26
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 4.79 1.75 8.27 1.38 3.28 2.45 1.76 4.22
Price to Tangible Book Value (P/TBV)		 0.00 0.00 4.79 1.75 8.27 1.38 3.28 2.45 0.00 0.00
Price to Revenue (P/Rev)		 2.73 2.31 6.45 1.34 4.28 2.13 2.87 1.18 0.65 0.63
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 53.50 27.71 2.44 7.53 2.54 1.31 2.24
Enterprise Value to Revenue (EV/Rev)		 0.00 6.95 5.04 0.58 3.90 0.99 2.30 1.15 1.19 0.87
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 -5.36 0.43 0.65 1.36 0.41 0.63 1.73 1.77 2.53
Long-Term Debt to Equity		 0.00 -5.36 0.43 0.42 1.36 0.41 0.40 1.73 1.73 2.51
Financial Leverage		 0.00 -0.07 -1.13 -1.02 -0.90 -0.73 -0.70 -0.43 0.52 1.18
Leverage Ratio		 0.00 -7.06 2.38 1.83 2.44 1.99 1.81 2.55 3.89 4.87
Compound Leverage Factor		 0.00 -8.56 2.81 2.09 3.04 2.28 2.05 3.11 5.31 6.20
Debt to Total Capital		 0.00% 122.95% 29.96% 39.43% 57.59% 29.32% 38.65% 63.42% 63.84% 71.65%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 14.24% 0.00% 0.00% 14.11% 0.00% 1.14% 0.54%
Long-Term Debt to Total Capital		 0.00% 122.95% 29.96% 25.19% 57.59% 29.32% 24.54% 63.42% 62.71% 71.11%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 778.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.65% 4.17%
Common Equity to Total Capital		 0.00% -801.38% 70.04% 60.57% 42.41% 70.68% 61.35% 36.58% 31.50% 24.18%
Debt to EBITDA		 0.00 -2.48 -1.63 -1.32 -1.74 -1.39 -1.18 -2.68 -1.93 -2.51
Net Debt to EBITDA		 0.00 -0.03 3.97 2.00 0.93 2.47 1.22 0.09 -1.25 -1.21
Long-Term Debt to EBITDA		 0.00 -2.48 -1.63 -0.85 -1.74 -1.39 -0.75 -2.68 -1.89 -2.49
Debt to NOPAT		 0.00 -3.10 -2.19 -1.65 -2.22 -1.83 -1.46 -2.77 -2.32 -3.01
Net Debt to NOPAT		 0.00 -0.04 5.34 2.50 1.19 3.25 1.51 0.09 -1.50 -1.45
Long-Term Debt to NOPAT		 0.00 -3.10 -2.19 -1.06 -2.22 -1.83 -0.93 -2.77 -2.28 -2.99
Altman Z-Score		 0.00 -5.13 2.70 -2.02 -2.07 -1.20 -1.97 -3.25 -3.89 -3.45
Noncontrolling Interest Sharing Ratio		 0.00% -3,392.60% 285.59% 0.00% 0.00% 0.00% 0.00% 0.00% 6.20% 13.71%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 3.09 8.44 3.19 4.75 7.34 2.98 4.73 1.86 2.02
Quick Ratio		 0.00 2.79 8.13 3.00 4.24 6.63 2.58 3.96 1.37 1.48
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -4.42 -16 -23 -22 -35 -22 -34 -60 -12
Operating Cash Flow to CapEx		 -2,636.11% -1,876.09% -2,036.70% -3,749.32% -3,889.04% -1,189.25% -940.32% -1,352.39% -2,114.39% -2,543.57%
Free Cash Flow to Firm to Interest Expense		 0.00 -1.57 -4.30 -6.15 -4.02 -8.67 -5.18 -6.21 -5.14 -1.41
Operating Cash Flow to Interest Expense		 -4.65 -3.97 -5.58 -8.27 -5.21 -6.96 -7.23 -5.91 -2.65 -2.42
Operating Cash Flow Less CapEx to Interest Expense		 -4.83 -4.18 -5.86 -8.49 -5.35 -7.55 -8.00 -6.34 -2.77 -2.52
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 1.04 0.68 0.58 0.55 0.50 0.51 0.61 0.58 1.06
Accounts Receivable Turnover		 0.00 9.48 10.68 10.28 7.17 7.44 6.12 4.86 3.83 7.49
Inventory Turnover		 0.00 3.90 5.08 5.91 3.56 2.27 2.00 2.31 3.36 17.92
Fixed Asset Turnover		 0.00 29.75 38.56 50.43 53.61 56.73 40.61 35.67 18.15 27.86
Accounts Payable Turnover		 0.00 3.83 3.97 3.67 2.76 2.90 4.60 5.47 2.62 7.05
Days Sales Outstanding (DSO)		 0.00 38.52 34.19 35.50 50.90 49.07 59.61 75.13 95.37 48.73
Days Inventory Outstanding (DIO)		 0.00 93.52 71.84 61.75 102.59 161.04 182.25 157.87 108.65 20.36
Days Payable Outstanding (DPO)		 0.00 95.23 91.92 99.39 132.27 126.04 79.35 66.75 139.36 51.81
Cash Conversion Cycle (CCC)		 0.00 36.81 14.12 -2.14 21.22 84.07 162.51 166.25 64.66 17.28
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -5.11 -3.15 0.68 6.94 22 20 32 68 58
Invested Capital Turnover		 0.00 -15.83 -12.79 -50.86 12.92 3.76 3.08 2.74 1.49 2.36
Increase / (Decrease) in Invested Capital		 0.00 -5.11 1.96 3.83 6.26 16 -2.56 12 36 -10
Enterprise Value (EV)		 0.00 281 266 36 192 55 150 82 89 130
Market Capitalization		 94 94 340 84 211 118 187 84 49 95
Book Value per Share		 $0.00 ($1,035.76) $4.04 $2.57 $1.34 $3.23 $2.10 $1.18 $0.91 $0.33
Tangible Book Value per Share		 $0.00 ($1,035.76) $4.04 $2.57 $1.34 $3.23 $2.10 $1.18 ($0.35) ($0.28)
Total Capital		 0.00 24 101 79 60 121 93 93 88 93
Total Debt		 0.00 30 30 31 35 35 36 59 56 66
Total Long-Term Debt		 0.00 30 30 20 35 35 23 59 55 66
Net Debt		 0.00 0.41 -74 -47 -19 -63 -37 -1.96 36 32
Capital Expenditures (CapEx)		 0.32 0.59 1.01 0.81 0.73 2.35 3.27 2.37 1.47 0.80
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -4.14 -3.67 -4.58 0.49 3.29 6.82 13 8.19 -2.83
Debt-free Net Working Capital (DFNWC)		 0.00 25 101 72 51 100 79 74 28 32
Net Working Capital (NWC)		 0.00 25 101 61 51 100 66 74 27 31
Net Nonoperating Expense (NNE)		 4.70 6.53 10 10 12 12 13 8.80 20 17
Net Nonoperating Obligations (NNO)		 0.00 0.41 -74 -47 -19 -63 -37 -1.96 36 32
Total Depreciation and Amortization (D&A)		 1.06 1.32 1.72 1.82 2.13 1.78 2.36 2.64 2.84 4.29
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -10.23% -6.95% -7.31% 0.99% 5.95% 10.45% 18.78% 10.94% -1.90%
Debt-free Net Working Capital to Revenue		 0.00% 61.86% 191.21% 114.93% 104.24% 180.12% 120.69% 103.69% 37.20% 21.14%
Net Working Capital to Revenue		 0.00% 61.86% 191.21% 96.97% 104.24% 180.12% 100.56% 103.69% 35.86% 20.80%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($76.95) ($86.34) ($2.69) ($1.58) $0.00 ($1.22) ($1.38) ($1.05) ($1.38) ($0.59)
Adjusted Weighted Average Basic Shares Outstanding		 146K 186K 18.05M 18.67M 0.00 25.48M 26.90M 28.66M 31.73M 65.95M
Adjusted Diluted Earnings per Share		 ($76.95) ($86.34) ($2.69) ($1.58) $0.00 ($1.22) ($1.38) ($1.05) ($1.38) ($0.59)
Adjusted Weighted Average Diluted Shares Outstanding		 146K 186K 18.05M 18.67M 0.00 25.48M 26.90M 28.66M 31.73M 65.95M
Adjusted Basic & Diluted Earnings per Share		 ($76.95) ($86.34) ($2.69) ($1.58) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 146K 186K 8.95M 18.38M 0.00 26.63M 28.36M 29.76M 65.81M 69.28M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.54 -9.53 -14 -19 -16 -19 -25 -21 -24 -22
Normalized NOPAT Margin		 -19.10% -23.56% -26.31% -30.09% -31.71% -34.88% -37.69% -29.98% -32.31% -14.75%
Pre Tax Income Margin		 -32.82% -39.72% -45.66% -46.35% -55.75% -56.39% -56.99% -42.31% -58.39% -26.24%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -5.12 -4.72 -5.53 -6.88 -4.04 -6.76 -7.74 -4.57 -2.73 -3.65
NOPAT to Interest Expense		 -3.56 -3.39 -3.76 -5.12 -2.87 -4.80 -5.78 -3.94 -2.07 -2.62
EBIT Less CapEx to Interest Expense		 -5.30 -4.93 -5.81 -7.10 -4.18 -7.35 -8.51 -5.00 -2.86 -3.75
NOPAT Less CapEx to Interest Expense		 -3.74 -3.60 -4.04 -5.34 -3.00 -5.39 -6.55 -4.38 -2.19 -2.71
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.24%
Augmented Payout Ratio		 0.00% 0.00% -14.37% 0.00% 0.00% -1.29% 0.00% 0.00% 0.00% -5.87%

Quarterly Metrics And Ratios for Neuronetics

This table displays calculated financial ratios and metrics derived from Neuronetics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 29,756,053.00 29,997,563.00 30,295,465.00 - 65,814,512.00 65,820,344.00 66,124,820.00 68,485,922.00 69,276,593.00 69,587,840.00 76,197,222.00
DEI Adjusted Shares Outstanding		 29,756,053.00 29,997,563.00 30,295,465.00 - 65,814,512.00 65,820,344.00 66,124,820.00 68,485,922.00 69,276,593.00 69,587,840.00 76,197,222.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.26 -0.33 -0.44 - -0.19 -0.15 -0.14 -0.10 -0.16 -0.05 -0.02
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 12.08% -6.59% 3.61% 10.73% 83.59% 131.66% 101.28% 85.73% 7.75% 9.08% 12.51%
EBITDA Growth		 37.80% -122.84% 13.20% -260.06% -81.51% 3.09% 7.21% 62.12% 27.86% 94.27% 125.64%
EBIT Growth		 34.75% -109.05% 12.40% -209.11% -78.06% -0.20% -0.08% 55.25% 25.93% 82.99% 108.17%
NOPAT Growth		 30.77% -15.76% 12.88% -159.07% -60.58% 5.28% 5.27% 56.03% 18.33% 81.37% 107.39%
Net Income Growth		 25.16% -100.61% -42.06% -135.84% -61.17% -0.07% 29.53% 43.17% 15.04% 64.79% 83.45%
EPS Growth		 28.95% -94.12% -33.33% -100.00% 22.22% 54.55% 70.45% 70.59% 23.81% 66.67% 84.62%
Operating Cash Flow Growth		 21.02% 43.75% 46.49% -503.00% -41.43% 29.48% 85.51% 110.56% 44.56% 71.23% 257.71%
Free Cash Flow Firm Growth		 -137.84% 29.91% 91.17% -185.42% -183.43% -464.90% -1,687.24% 114.95% 119.97% 127.44% 121.55%
Invested Capital Growth		 39.34% 3.48% -9.32% 111.60% 95.53% 97.75% 87.23% -14.82% -20.30% -17.26% -11.18%
Revenue Q/Q Growth		 -14.26% -5.55% 12.64% 21.39% 42.16% 19.18% -2.13% 12.01% -17.53% 20.65% 0.95%
EBITDA Q/Q Growth		 -86.42% -31.17% 5.94% -56.55% 6.03% 29.97% 9.94% 36.08% -78.96% 94.44% 502.84%
EBIT Q/Q Growth		 -71.11% -29.88% 8.47% -51.95% 1.44% 26.91% 8.58% 32.06% -63.15% 83.21% 143.91%
NOPAT Q/Q Growth		 -54.94% -24.03% 9.16% -48.41% 3.97% 26.84% 9.15% 31.12% -78.37% 83.31% 136.04%
Net Income Q/Q Growth		 -46.42% -24.88% -35.69% 4.95% -0.06% 22.46% 4.45% 23.35% -49.60% 67.87% 55.08%
EPS Q/Q Growth		 -58.82% -22.22% -33.33% 22.73% 38.24% 28.57% 13.33% 23.08% -60.00% 68.75% 60.00%
Operating Cash Flow Q/Q Growth		 -663.29% 58.64% -9.02% -58.69% -97.69% 79.38% 77.60% 215.67% -1,137.56% 89.30% 222.82%
Free Cash Flow Firm Q/Q Growth		 -0.81% 53.99% 72.91% -2,171.88% -0.11% 8.30% 14.31% 119.01% 33.72% 25.98% -32.71%
Invested Capital Q/Q Growth		 18.01% -6.54% -4.91% 101.75% 9.05% -5.48% -9.97% -8.22% 2.05% -1.88% -3.36%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 75.15% 74.04% 75.56% 66.21% 49.22% 46.60% 45.87% 51.95% 46.89% 51.06% 52.17%
EBITDA Margin		 -30.58% -42.47% -35.46% -45.73% -30.23% -17.77% -16.35% -9.33% -20.24% -0.93% 3.72%
Operating Margin		 -39.38% -51.71% -41.71% -50.99% -34.45% -21.15% -19.63% -12.07% -26.11% -3.61% 1.29%
EBIT Margin		 -34.72% -47.74% -38.80% -48.57% -33.67% -20.65% -19.29% -11.70% -23.15% -3.22% 1.40%
Profit (Net Income) Margin		 -45.20% -59.77% -72.00% -56.38% -39.68% -25.82% -25.21% -17.25% -31.29% -8.33% -3.71%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 130.20% 125.18% 185.58% 116.08% 117.85% 125.02% 130.66% 147.42% 135.17% 258.70% -264.63%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -61.79% -74.64% -59.73% -53.23% -38.37% -31.07% -36.76% -19.96% -41.47% -6.10% 2.41%
ROIC Less NNEP Spread (ROIC-NNEP)		 -4.20% -228.49% -126.49% -80.25% -60.40% -46.35% -51.93% -30.73% -53.11% -12.51% -3.47%
Return on Net Nonoperating Assets (RNNOA)		 0.59% -17.75% -63.51% -41.88% -40.65% -50.05% -71.84% -36.14% -72.31% -17.73% -4.25%
Return on Equity (ROE)		 -61.20% -92.39% -123.23% -95.12% -79.03% -81.13% -108.59% -56.10% -113.78% -23.83% -1.83%
Cash Return on Invested Capital (CROIC)		 -91.82% -60.83% -44.43% -119.81% -112.87% -116.28% -115.33% -18.84% -8.23% -6.02% -5.72%
Operating Return on Assets (OROA)		 -24.51% -34.89% -33.76% -28.33% -24.51% -19.83% -22.82% -12.36% -26.25% -3.75% 1.61%
Return on Assets (ROA)		 -31.92% -43.68% -62.65% -32.89% -28.88% -24.79% -29.82% -18.22% -35.48% -9.71% -4.27%
Return on Common Equity (ROCE)		 -61.20% -92.39% -123.23% -89.22% -74.23% -74.18% -97.92% -48.41% -97.95% -20.18% -1.57%
Return on Equity Simple (ROE_SIMPLE)		 -99.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -4.80 -5.95 -5.41 -8.03 -7.71 -5.64 -5.12 -3.53 -6.30 -1.05 0.38
NOPAT Margin		 -27.57% -36.20% -29.19% -35.69% -24.11% -14.80% -13.74% -8.45% -18.28% -2.53% 0.90%
Net Nonoperating Expense Percent (NNEP)		 -57.59% 153.85% 66.77% 27.02% 22.02% 15.28% 15.18% 10.77% 11.64% 6.41% 5.89%
Return On Investment Capital (ROIC_SIMPLE)		 -5.51% -7.52% -9.77% -9.13% -8.04% -6.41% -5.23% -3.81% -8.01% -1.26% 0.45%
Cost of Revenue to Revenue		 24.86% 25.96% 24.44% 33.79% 50.78% 53.40% 54.13% 48.05% 53.11% 48.94% 47.83%
SG&A Expenses to Revenue		 34.20% 37.37% 40.13% 47.93% 41.09% 31.88% 29.70% 31.93% 37.87% 27.43% 27.82%
R&D to Revenue		 13.49% 13.59% 13.04% 25.66% 5.05% 4.72% 4.03% 3.99% 3.96% 3.21% 2.84%
Operating Expenses to Revenue		 114.53% 125.75% 117.26% 117.20% 83.67% 67.74% 65.50% 64.02% 72.99% 54.67% 50.88%
Earnings before Interest and Taxes (EBIT)		 -6.05 -7.85 -7.19 -11 -11 -7.87 -7.20 -4.89 -7.98 -1.34 0.59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.33 -6.99 -6.57 -10 -9.67 -6.77 -6.10 -3.90 -6.97 -0.39 1.56
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.12 2.79 2.45 1.76 6.83 8.46 6.60 4.22 7.57 5.07 9.53
Price to Tangible Book Value (P/TBV)		 5.12 2.79 2.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 1.93 0.75 0.32 0.65 2.71 2.07 1.39 0.63 0.66 0.58 1.12
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 4.00 1.97 1.40 1.31 3.78 3.88 3.42 2.24 2.47 2.25 3.84
Enterprise Value to Revenue (EV/Rev)		 2.08 0.97 0.65 1.19 3.14 2.46 1.67 0.87 0.97 0.84 1.35
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 2.15 3.08 4.90 1.77 1.43 1.79 2.13 2.53 3.61 2.85 2.77
Long-Term Debt to Equity		 2.15 2.38 4.90 1.73 1.40 1.76 2.09 2.51 3.59 2.84 2.76
Financial Leverage		 -0.14 0.08 0.50 0.52 0.67 1.08 1.38 1.18 1.36 1.42 1.22
Leverage Ratio		 2.73 3.04 3.53 3.89 3.66 4.55 5.39 4.87 4.73 5.01 5.16
Compound Leverage Factor		 3.55 3.81 6.55 4.52 4.31 5.69 7.04 7.17 6.39 12.96 -13.66
Debt to Total Capital		 68.25% 75.51% 83.06% 63.84% 58.77% 64.22% 68.01% 71.65% 78.30% 74.06% 73.46%
Short-Term Debt to Total Capital		 0.00% 17.20% 0.00% 1.14% 1.04% 1.14% 1.02% 0.54% 0.32% 0.30% 0.30%
Long-Term Debt to Total Capital		 68.25% 58.31% 83.06% 62.71% 57.72% 63.08% 66.99% 71.11% 77.98% 73.76% 73.16%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 4.65% 4.25% 4.95% 4.08% 4.17% 4.83% 4.54% 4.38%
Common Equity to Total Capital		 31.75% 24.49% 16.94% 31.50% 36.98% 30.83% 27.91% 24.18% 16.88% 21.40% 22.16%
Debt to EBITDA		 -3.15 -2.63 -2.12 -1.93 -1.68 -1.70 -2.03 -2.51 -2.59 -3.56 -6.39
Net Debt to EBITDA		 -0.55 -0.71 -1.12 -1.25 -1.04 -1.17 -0.97 -1.21 -1.78 -2.10 -3.49
Long-Term Debt to EBITDA		 -3.15 -2.03 -2.12 -1.89 -1.65 -1.67 -2.00 -2.49 -2.58 -3.54 -6.37
Debt to NOPAT		 -3.09 -2.98 -2.39 -2.32 -2.08 -2.11 -2.52 -3.01 -2.99 -3.86 -5.91
Net Debt to NOPAT		 -0.54 -0.81 -1.27 -1.50 -1.29 -1.45 -1.20 -1.45 -2.05 -2.28 -3.22
Long-Term Debt to NOPAT		 -3.09 -2.30 -2.39 -2.28 -2.04 -2.07 -2.48 -2.99 -2.98 -3.84 -5.88
Altman Z-Score		 -2.77 -4.23 -6.22 -3.40 -2.16 -2.38 -2.37 -2.84 -3.51 -3.17 -2.59
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 6.20% 6.07% 8.57% 9.83% 13.71% 13.91% 15.33% 14.32%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.65 2.58 3.16 1.86 2.44 2.02 2.24 2.02 1.67 1.88 2.01
Quick Ratio		 4.70 2.15 2.41 1.37 1.90 1.36 1.64 1.48 1.05 1.26 1.38
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -16 -7.15 -1.94 -44 -44 -40 -35 6.58 8.80 11 7.46
Operating Cash Flow to CapEx		 -3,204.00% -806.66% -1,403.37% -9,658.43% -7,759.36% -1,390.48% -688.60% 420.37% -5,477.33% -241.73% 263.40%
Free Cash Flow to Firm to Interest Expense		 -8.51 -3.61 -0.31 -25.04 -22.92 -20.51 -15.69 2.84 3.14 5.22 3.48
Operating Cash Flow to Interest Expense		 -6.58 -2.51 -0.88 -4.89 -8.84 -1.78 -0.36 0.39 -3.36 -0.47 0.58
Operating Cash Flow Less CapEx to Interest Expense		 -6.79 -2.82 -0.94 -4.94 -8.96 -1.91 -0.41 0.30 -3.42 -0.67 0.36
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.71 0.73 0.87 0.58 0.73 0.96 1.18 1.06 1.13 1.17 1.15
Accounts Receivable Turnover		 5.43 4.76 4.57 3.83 4.09 5.14 7.31 7.49 7.22 7.37 9.65
Inventory Turnover		 2.50 2.57 2.40 3.36 6.06 8.79 13.87 17.92 17.97 15.11 17.01
Fixed Asset Turnover		 38.17 37.57 39.25 18.15 23.25 31.51 39.50 27.86 31.20 35.30 39.35
Accounts Payable Turnover		 4.99 4.67 5.78 2.62 5.70 7.05 8.66 7.05 7.92 7.13 7.32
Days Sales Outstanding (DSO)		 67.18 76.70 79.94 95.37 89.16 71.06 49.91 48.73 50.55 49.50 37.84
Days Inventory Outstanding (DIO)		 145.76 142.24 151.78 108.65 60.18 41.53 26.31 20.36 20.31 24.16 21.46
Days Payable Outstanding (DPO)		 73.16 78.11 63.17 139.36 64.09 51.80 42.15 51.81 46.06 51.22 49.88
Cash Conversion Cycle (CCC)		 139.78 140.82 168.55 64.66 85.26 60.78 34.07 17.28 24.81 22.45 9.42
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 38 36 34 68 74 70 63 58 59 58 56
Invested Capital Turnover		 2.24 2.06 2.05 1.49 1.59 2.10 2.68 2.36 2.27 2.41 2.67
Increase / (Decrease) in Invested Capital		 11 1.20 -3.47 36 36 35 29 -10 -15 -12 -7.08
Enterprise Value (EV)		 152 70 47 89 281 273 216 130 146 131 216
Market Capitalization		 142 54 23 49 242 230 181 95 100 90 178
Book Value per Share		 $0.93 $0.65 $0.31 $0.91 $0.54 $0.41 $0.41 $0.33 $0.19 $0.26 $0.25
Tangible Book Value per Share		 $0.93 $0.65 $0.31 ($0.35) ($0.04) ($0.16) ($0.21) ($0.28) ($0.41) ($0.33) ($0.29)
Total Capital		 87 79 55 88 96 88 98 93 79 83 84
Total Debt		 59 60 46 56 56 57 67 66 62 62 62
Total Long-Term Debt		 59 46 46 55 55 56 66 66 61 62 62
Net Debt		 10 16 24 36 35 39 32 32 42 37 34
Capital Expenditures (CapEx)		 0.38 0.62 0.39 0.09 0.22 0.25 0.11 0.22 0.17 0.42 0.47
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 19 17 15 8.19 15 12 2.30 -2.83 -0.08 -0.01 -0.82
Debt-free Net Working Capital (DFNWC)		 67 60 37 28 37 29 37 32 19 25 27
Net Working Capital (NWC)		 67 46 37 27 36 28 36 31 19 25 27
Net Nonoperating Expense (NNE)		 3.07 3.88 7.93 4.65 4.98 4.20 4.28 3.68 4.48 2.41 1.93
Net Nonoperating Obligations (NNO)		 10 16 24 36 35 39 32 32 42 37 34
Total Depreciation and Amortization (D&A)		 0.72 0.87 0.62 0.64 1.10 1.10 1.10 0.99 1.00 0.95 0.98
Debt-free, Cash-free Net Working Capital to Revenue		 25.70% 22.94% 20.80% 10.94% 17.22% 10.52% 1.77% -1.90% -0.05% -0.01% -0.52%
Debt-free Net Working Capital to Revenue		 92.00% 83.06% 50.28% 37.20% 41.17% 26.40% 28.45% 21.14% 12.62% 16.23% 17.08%
Net Working Capital to Revenue		 92.00% 64.18% 50.28% 35.86% 40.05% 25.50% 27.68% 20.80% 12.46% 16.07% 16.92%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.27) ($0.33) ($0.44) ($0.34) ($0.21) ($0.15) ($0.13) ($0.10) ($0.16) ($0.05) ($0.02)
Adjusted Weighted Average Basic Shares Outstanding		 29.47M 30.05M 30.27M 31.73M 61.47M 66.18M 67.31M 65.95M 69.59M 73.13M 77.00M
Adjusted Diluted Earnings per Share		 ($0.27) ($0.33) ($0.44) ($0.34) ($0.21) ($0.15) ($0.13) ($0.10) ($0.16) ($0.05) ($0.02)
Adjusted Weighted Average Diluted Shares Outstanding		 29.47M 30.05M 30.27M 31.73M 61.47M 66.18M 67.31M 65.95M 69.59M 73.13M 77.00M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 30.00M 30.30M 30.35M 65.81M 65.82M 66.12M 68.49M 69.28M 69.59M 76.20M 77.73M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.80 -5.95 -5.41 -8.03 -7.71 -5.64 -5.12 -3.53 -6.30 -1.05 0.38
Normalized NOPAT Margin		 -27.57% -36.20% -29.19% -35.69% -24.11% -14.80% -13.74% -8.45% -18.28% -2.53% 0.90%
Pre Tax Income Margin		 -45.20% -59.77% -72.00% -56.38% -39.68% -25.82% -25.21% -17.25% -31.29% -8.33% -3.71%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -3.31 -3.97 -1.17 -6.22 -5.60 -4.00 -3.26 -2.11 -2.84 -0.63 0.27
NOPAT to Interest Expense		 -2.63 -3.01 -0.88 -4.57 -4.01 -2.86 -2.32 -1.52 -2.24 -0.49 0.18
EBIT Less CapEx to Interest Expense		 -3.52 -4.28 -1.23 -6.27 -5.72 -4.12 -3.31 -2.20 -2.90 -0.83 0.06
NOPAT Less CapEx to Interest Expense		 -2.83 -3.32 -0.94 -4.62 -4.13 -2.99 -2.37 -1.62 -2.31 -0.69 -0.04
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.24% -0.46% -0.93% -2.25%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% -3.57% 0.00% 0.00% -5.87% -1.73% -3.68% -4.62%

Financials Breakdown Chart

Key Financial Trends

Neuronetics’ recent financial statements show meaningful revenue growth and improving operating performance, but the company remains unprofitable and dependent on external financing. Revenue reached $41.6 million in Q2 2026, up from $17.9 million in Q3 2023 and $22.5 million in Q4 2024. However, growth has recently become less consistent: Q2 revenue was roughly flat compared with $41.8 million in Q4 2025 after falling to $34.5 million in Q1 2026.

Profitability improved sequentially in Q2 2026. Gross profit increased to $21.2 million, producing a gross margin of approximately 51%, compared with about 47% in Q1. Selling, general and administrative expense and marketing expense also declined from the prior quarter. As a result, the operating loss narrowed to $1.5 million from $9.0 million in Q1, although interest expense of $2.1 million still contributed to a $3.5 million net loss.

Cash flow remains a key concern. Neuronetics used $9.4 million of operating cash in Q1 2026 before improving to a $1.0 million outflow in Q2. The company’s $6.0 million increase in cash during Q2 was primarily driven by a $8.0 million common-stock issuance, rather than internally generated cash. At June 30, 2026, the company held $19.2 million in cash and equivalents plus $5.8 million of restricted cash, while carrying approximately $61.8 million of long-term debt.

  • Revenue has expanded substantially over the reported period, rising from $17.9 million in Q3 2023 to $41.6 million in Q2 2026.
  • Q2 2026 gross profit increased to $21.2 million, and the gross margin improved to approximately 51% from 47% in Q1.
  • Operating losses narrowed sharply to $1.5 million in Q2 2026 from $9.0 million in Q1, supported by lower SG&A, marketing and research expenses.
  • Operating cash flow improved considerably, from a $9.4 million outflow in Q1 2026 to a $1.0 million outflow in Q2.
  • Current assets of $53.2 million exceeded current liabilities of $28.3 million at June 30, 2026, providing some short-term liquidity.
  • The Q2 cash increase of $6.0 million was primarily financing-driven, including a $8.0 million stock issuance, rather than the result of positive free cash flow.
  • Accounts receivable remained elevated at $16.0 million and inventories increased to $5.5 million, making working-capital management important as the business grows.
  • Neuronetics has reported recurring net losses, including a $3.5 million loss in Q2 2026 and a $10.8 million loss in Q1 2026.
  • Debt remains substantial at approximately $62.0 million, and cash interest paid was $1.9 million in Q2, limiting the benefit of improving operating results.
  • Shareholder dilution is a continuing risk: weighted-average basic shares increased to 73.1 million in Q2 2026 from 61.5 million in Q1 2025, while retained earnings stood at a deficit of $473.2 million.
11/15/26 10:53 AM ETAI Generated. May Contain Errors.

Neuronetics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Neuronetics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Neuronetics' net income appears to be on a downward trend, with a most recent value of -$39.14 million in 2025, falling from -$11.23 million in 2016. The previous period was -$43.73 million in 2024. Check out Neuronetics' forecast to explore projected trends and price targets.

Neuronetics' total operating income in 2025 was -$31.44 million, based on the following breakdown:
  • Total Gross Profit: $72.31 million
  • Total Operating Expenses: $103.74 million

Over the last 9 years, Neuronetics' total revenue changed from $34.23 million in 2016 to $149.16 million in 2025, a change of 335.8%.

In the past 12 quarters, Neuronetics' cash and equivalents has ranged from $10.97 million in Q2 2025 to $47.73 million in Q1 2024, and is currently $22.11 million as of their latest financial filing in Q3 2026.

Neuronetics had total debt of $66.31 million at the end of 2025, a 18.1% increase from 2024, and none in 2016.

Over the last 9 years, Neuronetics' book value per share changed from 0.00 in 2016 to 0.33 in 2025, a change of 32.7%.


Related Companies

Financial statements for NASDAQ:STIM last updated on 11/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel